Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 1;15(4):260-265.
doi: 10.1097/SPC.0000000000000580.

Cachexia and bladder cancer: clinical impact and management

Soum D Lokeshwar  1 , Benjamin H Press  1 , James Nie  1 , Zachary Klaassen  2 , Patrick A Kenney  1 , Michael S Leapman  1
Affiliations
Review

Cachexia and bladder cancer: clinical impact and management

Soum D Lokeshwar et al. Curr Opin Support Palliat Care. .

Abstract

Purpose of review: The purpose of this review is to describe the causes, management, and clinical outcomes associated with cachexia and related components including sarcopenia, among patients with bladder cancer (BCa).

Recent findings: Cachexia in patients with BCa is associated with poorer outcomes after radical cystectomy (RC), radiation, and chemotherapy. Nutritional supplements and novel pharmaceutical agents including magnolol, flucoidan and Anamorelin are currently undergoing investigation for their potential use in BCa patients with cachexia.

Summary: Cachexia is a hypercatabolic state thought to be caused by an immune-regulated release of cytokines and disruptions of molecular pathways within the tumor microenvironment and systemically. Nutritional deficiencies in patients with BCa also contribute to cachexia and sarcopenia. Patients with BCa -related cachexia and sarcopenia experience worse survival and therapeutic outcomes after RC, chemotherapy, and radiation therapy. Patients with cachexia also experience more postoperative complications after RC. The management of cachexia in patients with BCa remains challenging and requires timely identification, and multidisciplinary management including nutritional supplementation, physical therapy, palliative care, and pharmacological agents. Clinical trials and human studies are still required to determine which pharmacological agents are optimal for BCa cachexia.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70:7–30.
    1. Cancer Facts & Figures 2021. American Cancer Society, Atlanta, GA (2021). https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts... . [Accessed 26 October 2021]
    1. Fukushima H, Takemura K, Suzuki H, Koga F. Impact of sarcopenia as a prognostic biomarker of bladder cancer. Int J Mol Sci 2018; 19: doi:10.3390/ijms19102999. - DOI
    1. Sullivan ES, Daly LE, Power DG, Ryan AM. Epidemiology of cancer-related weight loss and sarcopenia in the UK and Ireland: incidence, prevalence, and clinical impact. JCSM Rapid Commun 2020; 3:91–102.
    1. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12:489–495.